البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
RIZATRIPTAN (RIZATRIPTAN BENZOATE)
CELLCHEM PHARMACEUTICALS INC.
N02CC04
RIZATRIPTAN
5MG
TABLET (ORALLY DISINTEGRATING)
RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5MG
ORAL
6
Prescription
SELECTIVE SEROTONIN AGONISTS
Active ingredient group (AIG) number: 0137841001; AHFS:
CANCELLED POST MARKET
2023-08-03
_CCP-Riztriptan ODT _ _Page 1 of 34_ PRODUCT MONOGRAPH PR CCP-RIZATRIPTAN ODT Rizatriptan Benzoate Orally Disintegrating Tablets 5 mg and 10 mg Rizatriptan (as Rizatriptan Benzoate) 5-HT 1 Receptor Agonist MIGRAINE THERAPY Date of Revision: June 19, 2017 CellChem Pharmaceuticals Inc. 30 Concourse Gate, Unit 1 Ottawa, Ontario K2E 7V7 Control # 205269 _CCP-Riztriptan ODT _ _Page 2 of 34_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................................3 INDICATIONS AND CLINICAL USE ......................................................................................3 CONTRAINDICATIONS ...........................................................................................................3 WARNINGS AND PRECAUTIONS ..........................................................................................4 ADVERSE REACTIONS ..........................................................................................................10 DRUG INTERACTIONS ..........................................................................................................16 DOSAGE AND ADMINISTRATION ......................................................................................18 OVERDOSAGE .........................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ....................................................................19 STORAGE AND STABILITY ..................................................................................................22 SPECIAL HANDLING INSTRUCTIONS ...............................................................................22 DOSAGE FORMS, COMPOSITION AND PACKAGING .....................................................23 PART II: SCIENTIFIC INFORMATION .............................................................................. 27 PHARMACEUTICAL INF اقرأ الوثيقة كاملة